Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 13/20 | 0.64 |
| ▸ | WNT1 | P04628 | 11/20 | 0.64 |
| ▸ | CLK2 | P49760 | 4/20 | 0.62 |
| ▸ | CLK3 | P49761 | 4/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5945798 | 0.86 | FLT3 (0.70) | DYRK1ACLK2ROCK1 | |
| SCHEMBL5945670 | 0.86 | DYRK1A (0.65) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14785616 | 0.86 | DYRK1A (0.64) | DYRK1AWNT1CLK2CLK3NPC1 | |
| SCHEMBL14785604 | 0.85 | DYRK1A (0.84) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL28291152 | 0.84 | FLT3 (0.74) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14792180 | 0.80 | DYRK1A (0.74) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14803375 | 0.80 | DYRK1A (0.74) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14785593 | 0.79 | DYRK1A (0.77) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL6223964 | 0.79 | DYRK1A (0.78) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14792839 | 0.79 | DYRK1A (0.78) | DYRK1AWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | claimed |
| JP-2006500348-A | — | — | 2006-01-05 | — | — | JP | claimed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | claimed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | disclosed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | DYRK1A 835/4885WNT1 1110/4885CLK2 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.